CD 2475 101

Drug Profile

CD 2475 101

Alternative Names: CD-2475-101; CD2475/101

Latest Information Update: 17 Jun 2015

Price : $50

At a glance

  • Originator Galderma
  • Class Antiacnes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acne vulgaris

Most Recent Events

  • 17 Jun 2015 No recent reports of development identified - Phase-II for Acne vulgaris in USA (PO)
  • 01 Jan 2012 Galderma completes a Phase-II trial in Acne vulgaris in USA (NCT01320033)
  • 14 Oct 2011 Galderma completes enrolment in its phase II trial for Acne vulgaris in USA (NCT01320033)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top